Stay updated on Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Sign up to get notified when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.

Latest updates to the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 to the history and removed the older funding-lapse notice and Revision: v3.4.1; this is an administrative update with no effect on the study data.SummaryDifference0.5%

- Check21 days agoChange DetectedNotice about lapse in government funding added; page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check28 days agoChange DetectedThe history page now includes a glossary toggle, green highlights for additions, red highlights for deletions, and visible revision labels (e.g., Revision: v3.4.0) to improve readability of changes.SummaryDifference0.7%

- Check42 days agoChange DetectedRevision: v3.3.4 updated in the page history (replacing v3.3.3).SummaryDifference0.1%

- Check64 days agoChange DetectedA new revision entry (v3.3.3) was added to the record history for NCT04249362, and the HHS Vulnerability Disclosure link was removed from the footer.SummaryDifference0.1%

- Check85 days agoChange DetectedNew Revision: v3.3.2 appears in the history, replacing v3.3.1; this reflects a site update with no changes to trial data or history content.SummaryDifference0.1%

Stay in the know with updates to Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.